Physician profile
Mark J Sterling
NPI 1306822069
$1,583.04
in general payments reported to CMS, 2019-2025
11 companies · $330 in 2025
The $330 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $799 · 2020: $124 · 2021: $130 · 2022: $80.19 · 2023: $88.89 · 2024: $31.10 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $450.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $351.56 | 2019-2023 | Spyglass |
| Janssen Biotech, INC. | $294.55 | 2019-2025 | Tremfya |
| Cook Medical LLC | $266.47 | 2019 | |
| Abbvie INC. | $217.18 | 2019-2025 | |
| Madrigal Pharmaceuticals | $208.00 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $83.41 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $69.98 | 2025 | Iqirvo |
| Ucb, INC. | $31.82 | 2019-2020 | |
| Medtronic, INC. | $27.77 | 2023 | Gi Genius |
| Pfizer INC. | $18.46 | 2020 | |
| Merck Sharp & Dohme LLC | $13.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sterling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.